QUTENZA ® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN ...

has completed recruitment for the Phase III clinical trial AV001 ... 8% topical system in post-surgical neuropathic pain (PSNP) and if successful could support an extension of the U.S. label.

The Phase 2 clinical trial of OK-101 is a double-masked, randomized, 12-week placebo-controlled study in patients with neuropathic corneal pain (NCP), according to the company. The study aims to ...

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trial The Phase 2 trial is designed as a randomized, placebo-controlled, ...

Credit: Getty Images The American Society of Pain and Neuroscience commissioned a multidisciplinary working group to develop evidence-based guidelines on use of injectable biologics for management ...

23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat corneal neuropathic pain (NCP), an ocular ...

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trial The Phase 2 trial is designed as a randomized, placebo ...